Abstract: The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Abstract: Provided is the use of a nanosecond pulsed electric field in improving cell stemness. Specifically, applying a nanosecond pulsed electric field to cells, especially stem cells, can effectively increase the expression level of stemness genes and reduce the methylation level of the cells, improve the stemness of the stem cells, and further facilitate the ability of the stem cells to receive induced differentiation.

Abstract: A data processing method, an apparatus, a device, and a medium in a blockchain fund settlement system are provided. A data processing method in a blockchain fund settlement system, performed by at least one processor of a settlement institution terminal, includes: querying, on a blockchain, a settlement request that is to be processed by the settlement institution terminal between a fund settlement initiator and a fund settlement recipient, the settlement request being generated by an initiator terminal of the fund settlement initiator and recorded on the blockchain; receiving the settlement request based on the querying; and generating a settlement result of a settlement performed according to the settlement request, and recording the settlement result on the blockchain.

Abstract: Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.

Abstract: Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.

Abstract: Provided herein are human arterial endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human arterial endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described.

Abstract: Methods for generating and using hematopoietic progenitor cells are described.

Abstract: The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Abstract: Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.

Abstract: The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Abstract: Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described.

Abstract: The present invention provides a photocurable composition prepared using mercapto benzophenone compounds as key raw materials. The present invention aims to solve the problems existing in the prior photo-curing technology that low-molecular photoinitiators are easy to remain and migrate, while macromolecular photoinitiators has low initiation efficiency due to a low content of effective components and also has the problem of certain migration. The photocurable composition in the present invention can be easily prepared and has high addition efficiency with ethylenically unsaturated compounds, and the photocurable composition obtained by addition has no residual mercapto and has features of high initiation activity and zero migration rates when it is used in photocurable coatings, binder and ink formula.

Abstract: The present invention relates to chemically defined and xenogeneic material-free methods for deriving endothelial cells from human pluripotent stem cells. In particular, the present invention provides highly efficient and reproducible methods of obtaining human endothelial cells from human pluripotent stem cells, where endothelial cells derived from the methods provided herein are suitable for clinically relevant therapeutic applications.

Abstract: The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Abstract: The present invention provides a photocurable composition prepared using mercapto benzophenone compounds as key raw materials. The present invention aims to solve the problems existing in the prior photo-curing technology that low-molecular photoinitiators are easy to remain and migrate, while macromolecular photoinitiators has low initiation efficiency due to a low content of effective components and also has the problem of certain migration. The photocurable composition in the present invention can be easily prepared and has high addition efficiency with ethylenically unsaturated compounds, and the photocurable composition obtained by addition has no residual mercapto and has features of high initiation activity and zero migration rates when it is used in photocurable coatings, binder and ink formula.

Abstract: The present invention provides a photocurable composition prepared using mercapto benzophenone compounds as key raw materials. The present invention aims to solve the problems existing in the prior photo-curing technology that low-molecular photoinitiators are easy to remain and migrate, while macromolecular photoinitiators has low initiation efficiency due to a low content of effective components and also has the problem of certain migration. The photocurable composition in the present invention can be easily prepared and has high addition efficiency with ethylenically unsaturated compounds, and the photocurable composition obtained by addition has no residual mercapto and has features of high initiation activity and zero migration rates when it is used in photocurable coatings, binder and ink formula.

Abstract: Apparatus for the conduct of electrochemiluminescence measurements includes an ECL chamber having a transparent window defining one wall of the chamber and a photodetector mounted closely adjacent thereto. An assay fluid is subject to a magnetic field and is electrically energized. Electrochemiluminescence induced in the fluid is measured by the photodetector.

Abstract: Apparatus for the conduct of electrochemiluminescence measurements includes an ECL chamber having a transparent window defining one wall of the chamber and a photodetector mounted closely adjacent thereto. An assay fluid is subject to a magnetic field and is electrically energized. Electrochemiluminescence induced in the fluid is measured by the photodetector.

Abstract: Apparatus for the conduct of electrochemiluminescence measurements includes an ECL chamber having a transparent window defining one wall of the chamber and a photodetector mounted closely adjacent thereto. An assay fluid is subject to a magnetic field and is electrically energized. Electrochemiluminescence induced in the fluid is measured by the photodetector.

Abstract: Apparatus for the conduct of electrochemiluminescence measurements includes an ECL chamber having a transparent window defining one wall of the chamber and a photodetector mounted closely adjacent thereto. An assay fluid is subject to a magnetic field and is electrically energized. Electrochemiluminescence induced in the fluid is measured by the photodetector.